Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State or other juri ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2020 Earnings Conference Call March 18, 2021 8:00 AM ET Company Participants Deanne Randolph - IR Frank Bedu-Addo - CEO Lauren V. Wood - CMO Seth L. Van Voorhees - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Company Trevor Allred - Oppenheimer & Company Operator Greetings and welcome to the PDS Biotechnology's Fourth Quarter and Fiscal Year 2020 Earnings Call and Webcast. [Operator Instructions]. A question-and-answer session will foll ...

CORPORATE OVERVIEW MARCH 2021 Frank Bedu-Addo Ph.D. President & CEO 6 Nasdaq: PDSB Developing powerful, safe, versatile immunotherapies Forward-Looking Statements This presentation contains forward-looking statements about PDS Biotechnology Corporation ("PDSB"), and its businesses, business prospects, strategies and plans, including but not limited to statements regarding anticipated pre-clinical and clinical drug development activities and timelines and market opportunities. All statements other than state ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (S ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2020 Earnings Conference Call November 12, 2020 8:00 AM ET Company Participants Deanne Randolph - Investor Relations Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Michael King - Interim Chief Financial Officer Conference Call Participants Joe Pantginis - H.C. Wainwright Ahu Demir - Noble Capital Jim Malloy - Alliance Global Partners Operator Greetings. Welcome to PDS Biotechnology's Third Quarter 2020 Earnings Call. At this time ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) Delaware 26-4231384 (State ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q2 2020 Earnings Conference Call August 13, 2020 8:00 AM ET Company Participants Deanne Randolph - Investor Relations Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Michael King - Interim Chief Financial Officer Conference Call Participants Operator Greetings, and welcome to PDS Biotechnology's Second Quarter 2020 Financial Results. At this time all, participants are in a listen-only mode. [Operator Instructions] As a reminder, this ...

PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2020 Results Earnings Conference Call May 13, 2020 8:00 AM ET Company Participants Alexander Lobo - Investor Relations, The Ruth Group Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer Conference Call Participants Name - Company Name Operator Greetings. Welcome to PDS Biotechnology's first quarter 2020 financial results. At this time, all participants are in listen-only mode. The brief question-and-answer session will follow the form ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from____________to_____________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or other ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________ Commission file number 001-37568 PDS Biotechnology Corporation (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorpor ...